Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pancreatic cells
Show results for
Products
Services
Applications

Companies

News
Articles
Books

Refine by
Date

  • Older

Pancreatic Cells Articles & Analysis: Older

15 news found

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

In contrast to T2D, which is primarily a chronic metabolic disease, in type 1 diabetes the insulin secreting cells of the pancreas are destroyed, which is deemed to be attributable to factors such as genetics and environmental triggers. ...

ByBayer AG


NIH/NIDDK Phase 1 SBIR Awarded July 2016

NIH/NIDDK Phase 1 SBIR Awarded July 2016

Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem ...

ByRegenerative Medical Solutions Inc. (RMS)


NIH/NIDDK Phase I SBIR Awarded Sept 2016

NIH/NIDDK Phase I SBIR Awarded Sept 2016

Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell ...

ByRegenerative Medical Solutions Inc. (RMS)


NIH/NIDDK Phase I SBIR Awarded Sept 2016

NIH/NIDDK Phase I SBIR Awarded Sept 2016

Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening ...

ByRegenerative Medical Solutions Inc. (RMS)


Peptides for Diabetes Research—a Special Offer of BOC Sciences

Peptides for Diabetes Research—a Special Offer of BOC Sciences

The absolute lack of insulin, due to destruction of the insulin producing pancreatic β-cells, is the particular disorder in type 1 diabetes while type 2 diabetes is mainly characterized by the inability of cells to respond to insulin. ...

ByBOC Sciences


New AMPK Pathways Offered to Support Metabolism Research

New AMPK Pathways Offered to Support Metabolism Research

AMPK regulates cellular events, including cell growth, metabolic reprogramming, and autophagy. AMPK has emerged as a potential therapeutic target for metabolic diseases such as type 2 diabetes and cancer. ...

ByCD BioSciences


Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American ...

ByVertex Pharmaceuticals


Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. ...

ByVertex Pharmaceuticals


Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab

Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab

The Company currently has a pipeline of five anti-glycan mAbs: SC129, SC134, SC88 and SC27 that target solid tumours including pancreatic, small cell lung, colorectal and gastric, and SC2811 that targets a glycolipid on T cell stem cells. ...

ByScancell


Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

IsletRx is an expanded population of allogeneic stem cells differentiated into functioning insulin producing pancreatic islet cells. ...

ByKadimastem Ltd.


Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality

Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality

Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stemâ„¢ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR). ...

ByTreefrog Therapeutics


SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting

SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting

Details related to the poster presentation are as follows: Title: A cancer organogram test as a guide for oncology treatments in solid tumors: an analysis of 628 tests in 419 patients First Author: Astrid Margossian, MD, PhD Senior Author: Carla Grandori, MD, PhD Abstract Number: 2602 Poster Session: Developmental Therapeutics— Immunotherapy About PARIS® Test The PARIS® ...

BySEngine Precision Medicine


AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

Adenosine has an immune-suppressive effect in tumors, and pre-clinical and early clinical evidence indicates that antagonists of the GPCR family of adenosine receptors are able to relieve that suppression and restore anti-tumor immune cell activity. EXS21546 is a non-furan, selective antagonist of the A2A receptor with low brain penetration. Using EXS21546, we show that activity ...

ByExscientia


Israeli Startup Wants to Cure Diabetes by Making Micro-pancreases. It Worked on Mice

Israeli Startup Wants to Cure Diabetes by Making Micro-pancreases. It Worked on Mice

Never mind better insulin shots or cell implants for diabetics: Betalin Therapeutics has a unique approach. ...

ByBetalin Therapeutics Ltd.


Diverse Biotech creates first new drug candidates and progresses them to Pre-Clinical Testing

Diverse Biotech creates first new drug candidates and progresses them to Pre-Clinical Testing

These NCEs will be targeting basal cell carcinoma, pancreatic cancer, and glioblastoma with the ultimate future goal of establishing new standards of care for cancer patients. ...

ByDiverse Biotech Inc

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT